No Resistance Consulting Group
Glenn Harnett MD is a seasoned medical professional with extensive experience in various leadership roles within the healthcare industry. Currently serving as Chief Executive Officer at No Resistance Consulting Group since March 2016, Glenn also held positions including Chief Medical Officer and VP of Business Development at Blockit from November 2018 to August 2019, and Managing Director at Merchant Medicine LLC from January 2018 to August 2018. As an Urgent Care Advisor at The George Washington University from January 2017 to June 2018, Glenn contributed to the Antibiotic Resistance Action Center. Previous roles include Chief Medical Officer at American Family Care and Emergency Medicine Physician at Georgia Emergency Associates, where responsibilities encompassed emergency department leadership and risk management. Glenn's educational background includes an MD from the Medical College of Georgia at Augusta University, a degree in Emergency Medicine from Emory University, and a Bachelor's degree in Psychology from the University of New Hampshire.
This person is not in any teams
No Resistance Consulting Group
No Resistance has the required experience, expertise, people, and resources to enable urgent care centers (even those with no previous clinical trial experience) to participate in vital clinical trials and add an ancillary income source. No Resistance starts by recruiting and vetting experienced urgent care operators who not only have access to the desired patient base but also have a genuine interest in participating in research and contributing to the common good. We then contract with sponsors whose trial protocols seek to recruit subjects that closely match our clinic populations and clinical presentations. We then contract with the trial sites and embed No Resistance employed experienced investigators and/or study coordinators within the urgent care practices. This business model virtually eliminates the clinic's administrative and time burden and enables our sites to maximize subject enrollment – without adversely affecting the clinic’s normal workflow. It is a win/win/win for No Resistance, the sponsor, and the trial site. We pay the urgent care site a portion of the subject-specific fees for each subject that is enrolled in the trial at their clinic. A pretty simple idea, highly effective. Urgent care patients universally express that their participation in these trials is a very positive component of their patient experience and consider urgent care clinics participating in research to be “cutting edge”.